The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Once Daily i.v. Busulfan and Fludarabine (i.v. Bu-Flu) Compares Favorably with i.v. Busulfan and Cyclophosphamide (i.v. BuCy2) as Pretransplant Conditioning Therapy in AML/MDS
Open accessAbstract
We postulated that fludarabine (Flu) instead of cyclophosphamide (Cy) combined with i.v. busulfan (Bu) as preconditioning for allogeneic hematopoietic stem cell transplantation (HSCT) would improve safety and retain antileukemic efficacy. Sixty-seven patients received BuCy2, and subsequently, 148 patients received Bu-Flu. We used a Bayesian method to compare outcomes between these nonrandomized patients. The groups had comparable pretreatment characteristics, except that Bu-Flu patients were older (46 versus 39 years, P < .01), more often had unrelated donors (47.3% versus 20.9%, P < .0003), and had shorter median follow-up (39.7 versus 74.6 months). To account for improved supportive care and other unidentified factors that may affect outcome ("period" effects), 78 acute myelogenous leukemia (AML) patients receiving Melphalan-Flu (MF), treated in parallel during this time (1997-2004) were used to estimate the period effect. The MF patients' outcomes worsened during this period. Therefore, the period effect is unlikely to explain the greatly improved outcome with Bu-Flu. Patients transplanted with Bu-Flu in the first complete remission (CR1) had a 3-year overall survival and event-free-survival (EFS) of 78% and 74%, respectively, whereas CR1 patients younger than age 41 had a 3-year EFS of 83%. These results support replacing BuCy +/- ATG with Bu-Flu +/- rabbit-antithymocyte globulin (ATG), and warrant a prospective comparison between allogeneic HSCT and conventional induction/consolidation chemotherapy for AML in CR1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Cited by
Kanakry, C. G., O'Donnell, P. V., Furlong, T., de Lima, M. J., Wei, W., Medeot, M., Mielcarek, M., Champlin, R. E., Jones, R. J., Thall, P. F., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0625 · Cited by 278
Self-citationPorrata, L. F., Ristow, K., Habermann, T., Inwards, D. J., Micallef, I. N., & Markovic, S. N. (2010) · American Journal of Hematology · doi:10.1002/ajh.21849 · Cited by 124
Ben-Barouch, S., Cohen, O., Vidal, L., Avivi, I., & Ram, R. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.238 · Cited by 71
Harris, A. C., Boelens, J. J., Ahn, K. W., Fei, M., Abraham, A., Artz, A., Dvorak, C., Frangoul, H., Freytes, C., Gale, R. P., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018016956 · Cited by 33
Metadata
- Authors
- Andersson, B. S., de Lima, M., Thall, P. F., Wang, X., Couriel, D., Korbling, M., Roberson, S., Giralt, S., Pierre, B., Russell, J. A., Shpall, E. J., Jones, R. B., & Champlin, R. E.
- Venue
- Biology of Blood and Marrow Transplantation
- Publisher
- Elsevier BV
- Published
- 2008-06
- Volume
- 14
- Issue
- 6
- Pages
- 672-684
- ISSN
- 1083-8791 (ISSN-L)
- OpenAlex
- W2167517686
- Cited by
- 167
- References
- 1
- FWCI
- 7.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Once Daily i.v. Busulfan and Fludarabine (i.v. Bu-Flu) Compares Favorably with i.v. Busulfan and Cyclophosphamide (i.v. BuCy2) as Pretransplant Conditioning Therapy in AML/MDS. https://app.cochat.ai/papers/10.1016/j.bbmt.2008.03.009
- The paper
- Andersson, B. S., de Lima, M., Thall, P. F., Wang, X., Couriel, D., Korbling, M., Roberson, S., Giralt, S., Pierre, B., Russell, J. A., Shpall, E. J., Jones, R. B., & Champlin, R. E. (2008). Once Daily i.v. Busulfan and Fludarabine (i.v. Bu-Flu) Compares Favorably with i.v. Busulfan and Cyclophosphamide (i.v. BuCy2) as Pretransplant Conditioning Therapy in AML/MDS. Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2008.03.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.